Biotinylated Human CD20 / MS4A1 Full Length Protein, His,Avitag™ (Nanodisc) (HEK293)

Source : 

Biotinylated Human CD20 Full Length, His,Avitag (CD0-H82E3) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # P11836-1).

 

Molecule : CD20

 

Synonyms : MS4A1,CD20,MS4A-1

 

Format : Powder

 

Category : MABSol® Biotin Labeled Proteins

 

Accession : NP_068769.2

 

Storage : -20℃

 

Shipping condition : Powder,RT

 

Molecular Weight : 36.9 kDa

 

Characteristics :

Nanodiscs are a new class of model membranes that are being used to solubilize and study a range of integral membrane proteins (mp，full length CD20) and membrane-associated proteins. The Nanodisc bilayer is bounded by a membrane scaffold protein (MSP1D1)

 

Endotoxin Level : Less than 1.0 EU per μg by the LAL method.

 

Buffer : 20 mM HEPES, 150 mM NaCl, pH7.5

 

Description :

B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.

 

References :

(1) Walport M, et al., 2008, Janeway's Immunobiology (7th ed.). New York: Garland Science.
(2) Bonilla FA, Bona CA., 1996, Textbook of Immunology. Boca Raton: CRC. p. 102.
(3) Cragg MS., 2005., Curr. Dir. Autoimmun. 8: 140–74.